Fused heterocyclic indane carboxamide CGRP receptor antagonists

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• X is selected from C(R4) or N;
• Y is selected from C(R5) or N;
• R2 is selected from hydrogen and C1-4alkyl;
• R1 is selected from the group consisting of:
• (1) C1-6alkyl, optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of:
• F, Cl, Br, hydroxy and C1-4alkoxy, (2) C3-6cycloalkyl, optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of:
• F, Cl, Br, hydroxy and C1-4alkoxy, and
• wherein R6, R7, R8, R9 and R10 are independently selected from the group consisting of:
• hydrogen, methyl, F, Cl and Br;
• R3 is selected from the group consisting of:
• (1) hydrogen;
• (2) C1-6alkyl, optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of:
• F, amino, hydroxy and C1-4alkoxy, said C1-4alkoxy optionally substituted with hydroxy;
• (3) C3-6cycloalkyl or a 5- or 6-membered heterocyclyl containing 1 to 3 heteroatoms selected from S, O and N, said C3-6cycloalkyl and heterocyclyl optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of:
• F and —CF3;
• and
• (4) phenyl;
• R4 is hydrogen or methyl;
• and
• R5 is hydrogen, F or CN.